Abstract
We monitored platelet activation by means of P-selectin and platelet monocyte aggregates (PMA) and platelet function by whole blood multiple electrode aggregometry and platelet adhesion under high shear in chronic immune thrombocytopenia patients to define changes in platelet activation during treatment with eltrombopag. Overall, platelet activation and function normalized with increasing platelet counts. However, P-selectin, which was already elevated before treatment, and PMA increased further transiently during the first weeks. The increases in P-selectin and in PMA indicate ongoing platelet activation during the early period of treatment.
Similar content being viewed by others
References
Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Engl J Med 346:995–1008
Semple JW, Provan D, Garvey MB, Freedman J (2010) Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol 17:590–595
Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H (2003) T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9:1123–1124
Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T, Bozzi V, Mezzasoma AM, Melazzini F, Balduini CL (2010) Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 116:5832–5837
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrere F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371:395–403
Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373:641–648
Sailer T, Lechner K, Panzer S, Kyrle PA, Pabinger I (2006) The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 91:1041–1045
Panzer S, Pabinger I (2009) Eltrombopag in chronic idiopathic thrombocytopenic purpura. Lancet 373:607–608
Bussel JB, Cheng G, Saleh MN, Vasey S, Aivado M, Brainsky A (2009) Thromboembolic events observed in eltrombopag clinical trials in chronic immune thrombocytopenic purpura. Blood (ASH Annual Meeting Abstracts) 114: Abstract 2423
Saleh MN, Bussel JB, Cheng G, Meddeb B, Mayer B, Bailey C, Aivado M (2009) Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: results from the EXTEND Study. Blood (ASH Annual Meeting Abstracts) 114: Abstract 682
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB (2010) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 377:393–402
Panzer S, Rieger M, Vormittag R, Eichelberger B, Dunkler D, Pabinger I (2007) Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Investig 37:814–819
Panzer S, Hocker L, Rieger M, Vormittag R, Koren D, Dunkler D, Pabinger I (2007) Agonist-inducible platelet activation in chronic idiopathic autoimmune thrombocytopenia. Eur J Haematol 79:198–204
Panzer S, Stegfellner M, Jungbauer L, Ay C, Kaider A, Mannhalter C (2010) Combined effects of genetic polymorphisms of P-selectin and P-selectin glycoprotein ligand-1 on the binding of platelets to monocytes. Thromb Res 125:475–477
Mandelbaum M, Koren D, Eichelberger B, Auerbach L, Panzer S (2005) Frequencies of maternal platelet alloantibodies and autoantibodies in suspected fetal/neonatal alloimmune thrombocytopenia, with emphasis on human platelet antigen-15 alloimmunization. Vox Sang 89:39–43
Psaila B, Bussel JB, Linden MD, Li YF, Barnard MR, Tate CM, Page LK, Feldman EJ, Frelinger AL, Michelson AD (2007) Comparison of platelet function and bleeding in thrombocytopenic patients with immune thrombocytopenic purpura (ITP) and chemotherapy-induced thrombocytopenia (CIT). ASH Annual Meeting Abstracts. 110
Rinder HM, Tracey JB, Recht M, DeCastro L, Rinder CS, McHugh C, Smith BR (1998) Differences in platelet alpha-granule release between normals and immune thrombocytopenic patients and between young and old platelets. Thromb Haemost 80:457–462
Gardiner EE, Thom JY, Al-Tamimi M, Hughes A, Berndt MC, Andrews RK, Baker RI (2010) Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. Br J Haematol 149:625–628
Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL (2007) Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109:4739–4741
Psaila B, Bussel JB, Linden MD, Li YF, Barnard MR, Tate CM, Page LK, Frelinger AL, Michelson AD (2007) In vivo effects of eltrombopag on human platelet function. ASH Annual Meeting Abstract 110:1301
Dole VS, Bergmeier W, Patten IS, Hirahashi J, Mayadas TN, Wagner DD (2007) PSGL-1 regulates platelet P-selectin-mediated endothelial activation and shedding of P-selectin from activated platelets. Thromb Haemost 98:806–812
Engelmann B, Luther T, Muller I (2003) Intravascular tissue factor pathway–a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost 89:3–8
Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B (2003) Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 197:1585–1598
Losche W, Scholz T, Temmler U, Oberle V, Claus RA (2004) Platelet-derived microvesicles transfer tissue factor to monocytes but not to neutrophils. Platelets 15:109–115
Panes O, Matus V, Saez CG, Quiroga T, Pereira J, Mezzano D (2007) Human platelets synthesize and express functional tissue factor. Blood 109:5242–5250
Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI (2001) Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104:1533–1537
Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR (2009) Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 37:1030–1037
Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, Sanderson S, Provan D (2010) Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 95:1167–1175
Acknowledgments
We thank Beate Eichelberger and Daniela Koren (Department of Blood Group Serology and Transfusion Medicine) for performing platelet function tests and Tanja Altreiter, MA (Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University Vienna) for proofreading the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haselboeck, J., Pabinger, I., Ay, C. et al. Platelet activation and function during eltrombopag treatment in immune thrombocytopenia. Ann Hematol 91, 109–113 (2012). https://doi.org/10.1007/s00277-011-1249-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-011-1249-5